| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 50mg | |||
| Other Sizes |
| Targets |
Seclazone acts primarily through cyclooxygenase (COX) inhibition, reducing prostaglandin synthesis and thereby alleviating pain and inflammation. As an NSAID prodrug, its active metabolites are responsible for the pharmacological effects observed in vivo. The compound does not appear to have a single defined molecular target beyond the COX enzymes, which are the classical targets of NSAIDs. By inhibiting COX-1 and COX-2, seclazone reduces the production of prostaglandins and thromboxanes from arachidonic acid, leading to its anti-inflammatory, analgesic, and antipyretic effects.
|
|---|---|
| ln Vitro |
In vitro, seclazone has been studied for its effects on epidermal DNA synthesis and cellular proliferation. It has been shown to inhibit epidermal DNA synthesis and epidermal cellular proliferation induced by phorbol ester tumor promoters. Additionally, seclazone was found to be a potent inhibitor of plasminogen activator production in tumor cell cultures. These findings suggest that beyond its COX-inhibitory activity, seclazone may have additional effects on cellular processes related to inflammation and tumor promotion. However, specific IC50 values for COX inhibition are not detailed in the available literature.
|
| ln Vivo |
Seclazone (oral, dietary, 220 mg/kg) prevents rats from developing adjuvant-induced polyarthritis [1]. Seclazone considerably lowers rats' fever that is brought on by giving them yeast suspension [1].
In vivo, seclazone has demonstrated significant anti-inflammatory and antipyretic activity in animal models. Oral administration of seclazone at 220 mg/kg in the diet prevents rats from developing adjuvant-induced polyarthritis. It also considerably lowers fever in rats induced by yeast suspension administration. Daily oral administration inhibits the development of adjuvant-induced polyarthritis in rats. These findings confirm its orally active anti-inflammatory and antipyretic properties, supporting its classification as an NSAID. |
| Enzyme Assay |
Non-cellular in vitro assays for seclazone typically involve studying its mechanism of action as a COX inhibitor. A standard protocol uses purified COX-1 or COX-2 enzymes in a cell-free system. The enzyme is incubated with arachidonic acid substrate and varying concentrations of seclazone or its active metabolites. The production of prostaglandin PGE2 is measured using an ELISA or a radiometric assay. The IC50 for COX inhibition is determined from the concentration-response curve. Alternatively, the compound's antioxidant activity can be assessed using DPPH radical scavenging assays, where the reduction in absorbance is measured spectrophotometrically.
|
| Cell Assay |
Cellular assays for seclazone are performed using cell lines such as macrophages or fibroblasts. Cells are pre-treated with seclazone at various concentrations and then stimulated with an inflammatory stimulus such as lipopolysaccharide (LPS). After stimulation, the culture media is collected, and the levels of PGE2 and other inflammatory mediators are measured by ELISA. The expression of inflammatory genes (e.g., COX-2, TNF-α, IL-1β) can be assessed by RT-PCR. Cell viability is measured using an MTT assay to ensure that the observed effects are not due to cytotoxicity.
|
| Animal Protocol |
Animal/Disease Models: Male Charles River rat (150-170 g) [1]
Doses: 220 mg/kg Route of Administration: po (po (oral gavage)) dietary, daily Experimental Results: Inhibition of adjuvant-induced polyarthritis In vivo animal studies for seclazone are conducted in rodent models of inflammation and fever. For the adjuvant-induced polyarthritis model, rats are injected with Freund's complete adjuvant to induce arthritis. Seclazone is administered orally in the diet at 220 mg/kg. The development of arthritis is assessed by measuring paw swelling and evaluating clinical scores. For the antipyretic model, rats are given a yeast suspension to induce fever. Seclazone is administered orally, and rectal temperature is measured at various time points to assess its antipyretic effect. |
| ADME/Pharmacokinetics |
Seclazone is orally bioavailable, as demonstrated by its efficacy when administered orally in animal models. It has a molecular weight of 225.63 and is a small molecule with drug-like properties. For in vivo studies, it can be formulated in standard vehicles for oral administration. Detailed pharmacokinetic parameters such as half-life, Cmax, and bioavailability have not been fully reported in the available literature. However, its oral activity and efficacy in animal models suggest it is absorbed and reaches sufficient concentrations to exert its pharmacological effects.
|
| Toxicity/Toxicokinetics |
Detailed toxicological data for seclazone have not been extensively reported in the available literature. As a research chemical, it is not intended for human use and is strictly for preclinical research purposes. Standard safety precautions should be followed when handling seclazone, including the use of personal protective equipment. No specific toxicity data, such as LD50 values, are available in the provided literature. As an NSAID, it may share common side effects of this class, such as gastrointestinal irritation, but specific data are not available.
|
| References |
[1]. F M Berger, et al. The pharmacological properties of seclazone (7-chloro-3,3a-dihydro-2H, 9H-isoxazolo (3,2-b) (1,3) benzoxazin-9-one) a new anti-inflammatory agent. Pharmacology. 1973;9(3):164-76.
|
| Additional Infomation |
Seclazone is a synthetic NSAID prodrug that has been investigated for its anti-inflammatory, analgesic, antipyretic, and diuretic properties. It acts primarily through COX inhibition, reducing prostaglandin synthesis. The compound was studied as a potential therapeutic for arthritis and inflammatory disorders but was not widely marketed. In research, it serves as a reference compound for studying NSAID pharmacology, prodrug design, and inflammation biology. Seclazone is not a clinically approved drug and has not entered recent clinical trials. Its primary value is as a research tool for inflammation biology and prodrug development.
|
| Molecular Formula |
C10H8CLNO3
|
|---|---|
| Molecular Weight |
225.628
|
| Exact Mass |
225.019
|
| CAS # |
29050-11-1
|
| PubChem CID |
34443
|
| Appearance |
Off-white to light yellow solid powder
|
| LogP |
1.773
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
15
|
| Complexity |
286
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
ClC1C=CC2=C(C(N3OCCC3O2)=O)C=1
|
| InChi Key |
XWXVKXXKKLBDDJ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C10H8ClNO3/c11-6-1-2-8-7(5-6)10(13)12-9(15-8)3-4-14-12/h1-2,5,9H,3-4H2
|
| Chemical Name |
7-chloro-3,3a-dihydro-2H-[1,2]oxazolo[3,2-b][1,3]benzoxazin-9-one
|
| Synonyms |
Seclazone W 2354 W-2354
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~14.29 mg/mL (~63.33 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.4320 mL | 22.1602 mL | 44.3203 mL | |
| 5 mM | 0.8864 mL | 4.4320 mL | 8.8641 mL | |
| 10 mM | 0.4432 mL | 2.2160 mL | 4.4320 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
